2025 Philly Momentum: In Vivo CAR-T & IIT Pathways Redefining Advanced Therapies

​🌟 2025 Philly Momentum: In Vivo CAR-T & IIT Pathways Redefining Advanced Therapies

​📅 Date: October 23, 2025

​🕞 Time: 3:30 PM – 7:00 PM

​📍 Venue: Temple University Center City, 1515 Market Street, Philadelphia

​Join us for an exclusive gathering at the 2025 Philly Momentum: In Vivo CAR-T& IIT Pathways Redefining Advanced Therapies where thought leaders, scientists, and industry innovators will explore how In Vivo CAR-T and Investigator-Initiated Trials (IIT) are reshaping the landscape of advanced therapies.

​Event Highlights:

• ​CMC-Driven Strategies: Learn how China’s IIT framework is advancing In Vivo CAR-T and CGT development.

• ​Nonclinical Science Trends: Compare China IIT and U.S. IND decision frameworks to uncover regulatory innovation opportunities.

• ​Panel Discussion: Gain insights from leaders across government, investment, scientific, regulatory, and commercial sectors on the emerging U.S.–China Collaboration and business opportunities in drug discovery and development.

​ It offers a unique opportunity to network with key stakeholders, exchange ideas, and shape the future of global biopharma innovation.

​Free ticket and Networking Dinner included.

​ Agenda

​3:30- 4:00PM Registration and light snacks

​4:00– 4:10PM — Welcome & Opening Remarks

​• Hosted by GB·Partner leadership • Acknowledgement of sponsors and supporting collaborators • Opening remark: Rebecca L Grant Senior Director of Life science & Innovation at Phiadelphia Department of Commerce

​4:10– 4:35PM —Keynote -From Bench to Bedside: CMC-Driven Strategies with China IIT to Advance In Vivo CAR-T and CGT Shelley Wu Head of Business development at Porton Advanced 4:35–5:00 PM ---Keynote-- Strategic CAR-T Development: Nonclinical Sicence Trends and China IIT VS U.S. IND Decision FrameworkSean Chen Chief Scientific Officer at Innostar

​5:00– 5:50 PM —Panel discussion

​Topic: Accelerating Advanced Therapies, with a focus on In Vivo CAR-T and IIT Pathways and U.S.-China Complementarity Investment, Scientific, Regulatory, and Commercial Perspectives

​Panelists:

​Dong Geng SVP, Head of Early-stage Drug Development at Legned Biotech

​Shoubai Chao( Cansinotech COO, they have Venture Fund)

​Sara Johnson (Partner at Advantary Capital Partners)

​Sean Chen (Innostar CSO）

​Shelley Wu (Head of Business Development at Porton advanced)

​Interius  (TBD)

​5:50-6:00 pm Closing Remark

​6:00-7:00pm Meal & Networking

​Thank you! We hope this event will create a strong momentum and make a meaningful impact for Philly Advanced therapy International.

​Best,

​GB-Partner Team